1. "2010"
Formats
  1. Journal Article (2028)
  2. Meeting Abstract (717)
  3. Book Section (199)
  4. Book Whole (15)
  5. Conference Paper (10)
Groups
  1. Department of Medicine (846)
  2. Surgery (812)
  3. GSK Faculty (604)
  4. Sloan Kettering Institute Faculty (501)
  5. Solid Tumor Oncology Division (494)
  6. Survivorship Research (462)

More Groups

People
  1. Richard Barakat (59)
  2. Dennis Chi (58)
  3. Victor Reuter (57)
  4. Nadeem Abu-Rustum (53)
  5. Peter Scardino (49)
  6. Robert Soslow (49)

More People

Years
  1. 2010 (2969)
Publications
  1. Journal of Clinical Oncology (283)
  2. Cancer Research (79)
  3. Blood (78)
  4. International Journal of Radiation Oncology, Biology, Physics (78)
  5. Modern Pathology (72)
  6. Gynecologic Oncology (67)

More Publications

Publishers
  1. Elsevier Inc. (383)
  2. American Society of Clinical Oncology (284)
  3. Elsevier Science, Inc. (183)
  4. Springer (177)
  5. Lippincott Williams & Wilkins (153)
  6. Nature Publishing Group (144)

More Publishers

Results (2969)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival
    Meeting Abstract

    Shustov, A. R.; Pro, B.; Horwitz, S. M.; Jacobsen, E. D.; Boyd, A.; Fruchtman, S. M.; O'Connor, O.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Haque, S.; Ghossein, R. A.; Lisa, D. M.; Schoder, H.; Baum, M. S.; Shaha, A. R.; Tuttle, R. M.; Pfister, D. G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060)
    Meeting Abstract

    Shah, M. A.; Smyth, E. C.; Shibata, S.; Yong, W.; Tang, L. H.; Janjigian, Y. Y.; Kelsen, D. P.; Schwartz, G. K.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Impact of dermotologic toxicities on quality of life in patients receiving anticancer therapies
    Meeting Abstract

    Rosenbaum, S. E.; Balagula, Y.; Dusza, S. W.; Hensley, J.; Agulnik, M.; Brieva, J.; Lacouture, M. E.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial
    Meeting Abstract

    Sabbatini, P.; Berek, J. S.; Casado, A.; Cwiertka, K.; Pinter, T.; Pluzanska, A.; Scambia, G.; Pujade-Lauraine, E.; Vermorken, J. B.; Pfisterer, J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Meeting Abstract

    Riely, G. J.; Janjigian, Y. Y.; Azzoli, C. G.; Pietanza, M.; Krug, L. M.; Rizvi, N. A.; Kris, M. G.; Miller, V. A.; Pao, W.; Ginsberg, M. S.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG)
    Meeting Abstract

    Rodeberg, D. A.; Wharam, M. D.; Lyden, E.; Stoner, J. A.; Brown, K. L.; Wolden, S. L.; Paidas, C. N.; Donaldson, S. S.; Hawkins, D. S.; Arndt, C. A.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • The role of octreotide imaging in detecting neuroendocrine tumors (NETs) in 2010: Do we still need it?
    Meeting Abstract

    Saltz, L.; Gollub, M.; Reidy, D. L.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial
    Meeting Abstract

    Scher, H. I.; Chi, K. N.; De Wit, R.; Berry, W. R.; Albers, P.; Henick, B.; Venner, P.; Heidenreich, A.; Chu, L.; Heller, G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer
    Meeting Abstract

    Schrag, D.; Weiser, M. R.; Goodman, K. A.; Gonen, M.; Cercek, A.; Reidy, D. L.; Temple, L. K.; Wong, W. D.; Paty, P.; Saltz, L.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save